Mario Campone
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 307
- Cancer Treatment and Pharmacology 166
- HER2/EGFR in Cancer Research 117
- Cancer Cells and Metastasis 21
-
- Advanced Breast Cancer Therapies 176
- Co-authors
- Bella Kaufman (12 shared papers)Jean-Marc Ferrero (20 shared papers)José Baselga (23 shared papers)Hope S. Rugo (45 shared papers)Fabrice André (68 shared papers)Eva Ciruelos (16 shared papers)Javier Cortés (23 shared papers)L. Campion (27 shared papers)
- Journals
- Journal of Clinical Oncology (119 papers)Cancer Research (79 papers)Annals of Oncology (69 papers)Breast Cancer Research and Treatment (22 papers)European Journal of Cancer (15 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Mario Campone
524 papers receiving 24.3k citations
Mario Campone's Hit Papers
Peers
Comparison fields: 5 of 165
- Oncology 12.3k
- Cancer Research 5.5k
- Pulmonary and Respiratory Medicine 7.4k
- Genetics 2.5k
- Radiology, Nuclear Medicine and Imaging 2.4k
Countries citing papers authored by Mario Campone
This map shows the geographic impact of Mario Campone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Campone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Campone more than expected).
Fields of papers citing papers by Mario Campone
This network shows the impact of papers produced by Mario Campone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Campone. The network helps show where Mario Campone may publish in the future.
Co-authors
The 25 scholars most cited alongside Mario Campone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 546 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2006 | 2514 |
| 2 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 1644 |
| 3 | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2015 | 1453 |
| 4 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer Hit paper breakdown → | 2017 | 1170 |
| 5 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2013 | 705 |
| 6 | Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Hit paper breakdown → | 2012 | 529 |
| 7 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer Hit paper breakdown → | 2009 | 504 |
| 8 | 2009 | 485 | |
| 9 | 2009 | 431 | |
| 10 | Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma Hit paper breakdown → | 2013 | 421 |
| 11 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Hit paper breakdown → | 2014 | 416 |
| 12 | 2006 | 405 | |
| 13 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Hit paper breakdown → | 2020 | 391 |
| 14 | Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Hit paper breakdown → | 2013 | 389 |
| 15 | 2007 | 383 | |
| 16 | 2017 | 350 | |
| 17 | 2011 | 317 | |
| 18 | 2013 | 254 | |
| 19 | 2014 | 251 | |
| 20 | 2006 | 236 |
About Mario Campone
Mario Campone is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 546 papers that have together received 24.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (176 papers), Cancer Treatment and Pharmacology (166 papers), HER2/EGFR in Cancer Research (117 papers), Breast Cancer Treatment Studies (69 papers), PI3K/AKT/mTOR signaling in cancer (47 papers), Cancer Genomics and Diagnostics (39 papers), Estrogen and related hormone effects (28 papers) and Cancer Cells and Metastasis (21 papers). The work is most often cited by research in Oncology (12.3k citations), Cancer Research (5.5k citations), Pulmonary and Respiratory Medicine (7.4k citations), Genetics (2.5k citations) and Radiology, Nuclear Medicine and Imaging (2.4k citations). Mario Campone has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Bella Kaufman, Jean-Marc Ferrero, José Baselga, Hope S. Rugo, Fabrice André, Eva Ciruelos, Javier Cortés, L. Campion, David Cameron and Pascal Jézéquel. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.